297 results about "Infective disorder" patented technology

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention belongs to the technical field of medicines, and particularly relates to application of sesquiterpenoids and / or pharmaceutically acceptable salts thereof in preparation of medicines for treating or preventing infectious diseases caused by staphylococcus aureus. The invention relates to the field of medicines, in particular to application in preparation of medicines for treating or preventing infectious diseases caused by drug-sensitive staphylococcus aureus or drug-resistant staphylococcus aureus. The structure of the sesquiterpenoids is shown as a formula I in the specification. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low. The sesquiterpenoids shown in the formula I have a very good activity inhibition effect on staphylococcus aureus for the first time, and the sesquiterpenoids have a very good activity inhibition effect on staphylococcus aureus with drug sensitivity, drug medium or drug resistance.

The invention belongs to the technical field of biological detection, and particularly discloses a targeted sequencing primer group and a kit for detecting common pathogens of children and drug-resistant genes thereof. The primer group comprises 145 primer pairs of common children pathogen primer groups and 67 primer pairs of drug-resistant gene primer groups of the common children pathogen primer groups. According to the kit provided by the invention, nucleic acid in a clinical sample is directly extracted, 212 pairs of specific primers are adopted to realize multi-targeted amplification of a pathogen target area, a high-throughput sequencing platform is adopted to accurately identify pathogens and drug-resistant mutant genes thereof, 72 common children pathogens and drug-resistant genes thereof can be detected at the same time, and the kit has a wide application prospect. More accurate diagnosis information is provided for clinic, a key technical support is provided for early-stage accurate treatment of children infectious diseases, and the technical problems that in the prior art, in children pathogen detection, the detection speed is low, the number of missed detection is large, and the drug-resistant blind area is large are solved.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention discloses a gamma delta T cell efficient amplification method and application, and belongs to the technical field of cell biology. The amplification method comprises the following steps: separating PBMC (peripheral blood mononuclear cells) by adopting a density gradient centrifugation method, carrying out initial culture through a polylysine coated container, carrying out three-stage dynamic stimulation, combining with an X-VIVO 15 culture medium of 5-8% autoserum, and finally carrying out anti-gamma delta TCR magnetic bead separation to obtain high-purity cells. Through collaborative optimization of stepped factor combination, staged container coating and a low-serum system, the amplification multiple of the gamma delta T cells reaches 150-180 times, the purity is larger than or equal to 90% after purification, the cytotoxicity and the survival ability are remarkably improved, the gamma delta T cells can be efficiently used for immunotherapy of tumors and infectious diseases, and stable technical support is provided for clinical transformation of the gamma delta T cells.

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The invention discloses a swelling microneedle patch and a preparation method thereof. The swelling microneedle patch comprises a backing and a swelling microneedle array adhered to the backing, the swelling microneedle array comprises a plurality of microneedles; the microneedle is in the shape of a cone or a rectangular pyramid; the height of the microneedle is 100 to 1000 [mu] m; the diameter of the tip end of the microneedle is 5-30 microns; the diameter of the bottom of the microneedle is 50-500 [mu] m; and the center-to-center distance between every two adjacent microneedles is 50-2000 microns. The swelling microneedle patch provided by the invention can overcome the barrier action of cuticle to penetrate subcutaneously and absorb subcutaneous tissue interstitial fluid, and is simple in preparation process, low in cost and high in universality. The patch is combined with a colloidal gold lateral chromatography test strip, so that the limitations that in-vitro diagnosis of infectious diseases depends on a blood sample, professional medical personnel are needed for operation, the subject compliance is poor and the like can be solved, and the patch is suitable for rapid screening and diagnosis of the infectious diseases.

The present application provides detection and prognosis of infectious diseases. In particular, the present application provides fragment length profiles of nucleic acid libraries, methods of generating fragment length profiles of nucleic acid libraries, and methods of using the fragment length profiles for diagnosis and / or prognosis. The present application further provides methods, compositions, and kits for determining the stage or site of infection in a subject.

Provided herein are hantivirus antibodies. These hantivirus antibodies bind to the Gn and / or Gc subunits of a hantavirus glycoprotein and have broad neutralizing activity against an epitope of different hantavirus species. Such antibodies are used in methods of inducing an immune response and methods of inhibiting hantavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.

The present invention provides a lipid material for nucleic acid delivery, wherein the lipid material comprises a compound having structure I. The present invention also provides use of the lipid material for nucleic acid delivery in the preparation of a therapeutic drug for one or more selected from an infectious disease, a tumor disease, a congenital hereditary disease, and an immune disease. By means of the lipid material provided in the present invention and adopting a nucleic acid drug carrier strategy with high efficiency and low toxicity, a novel ionizable lipid and an auxiliary lipid material are mixed to encapsulate nucleic acid drugs, so that efficient and safe delivery of the nucleic acid drugs in vivo is achieved, and the druggability of the nucleic acid drugs is improved.

The invention discloses a method and system for synchronously detecting host chromatin openness and in-vivo microbiome based on transposase, and belongs to the technical field of biological sequencing data analysis. According to the method, transposase is used for selectively fragmenting an open chromatin region of a host, and a microbial genome is almost randomly cut, so that synchronous enrichment of host and microbial DNA is realized; after high-throughput sequencing library construction and double-end sequencing, sequencing data is split into host source and non-host source reads through bioinformatics analysis, host chromatin state and microorganism composition are analyzed respectively, and a microorganism-host epigenetic regulation network is constructed; the invention further provides a matched DNA sequencing library and an analysis system, multi-scene research of infectious diseases, intestinal microecology, tumor microenvironment and the like is supported, a public database can be reanalyzed, and potential microbial interaction signals are mined. According to the method, the host-microorganism interaction research efficiency is remarkably improved, and a high-sensitivity and integrated technical scheme is provided for epigenetic regulation mechanism analysis.

The present invention relates to a device for intravascular drug delivery, preferably an implant for intravascular drug delivery. The invention also relates to a device for a method for preventing or treating neurological diseases, neoplastic diseases, cardiac diseases, vascular diseases, immune diseases, carcinoids, infectious diseases and / or edema.

This invention discloses an alkaloid compound and its uses. Specifically, the invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts, or prodrugs of compounds of formula (I), and also to pharmaceutical compositions comprising said compounds and their uses. In particular, this alkaloid compound has a significant inhibitory effect on angiogenesis and can be used as a medicament for the prevention or treatment of tumors, inflammation, ophthalmic diseases, abnormal fibrosis or scar formation, cardiovascular and cerebrovascular diseases, nervous system diseases, infectious diseases, metabolic diseases, and diseases related to abnormal angiogenesis in mammals.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Z34B3 and application thereof. The amino acid sequence of the antibacterial peptide Z34B3 provided by the invention is shown as SEQ ID NO: 1, the secondary structure is an alpha helix, the molecular weight is small, and the antibacterial peptide Z34B3 can change the cell membrane permeability of various gram-negative bacteria including pasteurella multocida, escherichia coli and acinetobacter baumannii, inhibit the generation of cell membranes and play antibacterial and bactericidal roles. Moreover, the antibacterial peptide Z34B3 provided by the invention has low hemolytic activity and no cytotoxicity, and can be applied to preparation of products with bacteriostatic and bactericidal effects and preparation of drugs for preventing and / or treating bacterial infectious diseases. Furthermore, the C tail end of the antibacterial peptide Z34B3 is subjected to amidation modification, and compared with non-modification treatment, the stability can be improved.

The present disclosure relates to smallpox vaccines and stem cells for treating diseases. Described herein are methods and compositions for treating an inflammatory disease or an infectious disease in a subject in need thereof by administering a poxvirus and a stem cell to the subject, wherein the disease is not a cancer. For example, the disease can be a chronic inflammatory disease (e.g., an autoimmune disease).

The present invention relates to cytokine conjugates for the treatment of proliferative and infectious diseases, and discloses interleukin (IL) conjugates (e.g., IL-2 conjugates) and uses in the treatment of one or more indications. Also described are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

This invention belongs to the field of pharmaceutical technology, specifically relating to the use of a sesquiterpene compound and / or its pharmaceutically acceptable salt in the preparation of medicaments for treating or preventing infectious diseases caused by Staphylococcus aureus, particularly in the preparation of medicaments for treating or preventing infectious diseases caused by drug-sensitive or drug-resistant Staphylococcus aureus. The structure of the sesquiterpene compound of this invention is shown in Formula I: [Formula I]. The sesquiterpene compound used in this invention is derived from *Chrysanthemum indicum*, which is widely available and has low production costs. This invention is the first to discover that the sesquiterpene compound shown in Formula I exhibits very good inhibitory activity against Staphylococcus aureus, including very good inhibitory activity against drug-sensitive, drug-neutral, or drug-resistant Staphylococcus aureus.

The invention relates to the field of biological medicine, and provides an anti-virus infection effect and application of RBM22. Specifically, the invention relates to application of the RBM22 protein, a nucleic acid molecule for coding the protein, and an accelerant or a recombinant expression vector of the protein in preparation of products for treating virus infectious diseases and / or diseases and / or symptoms related to virus infection, and also provides a corresponding medicine or a medicine composition of the RBM22 protein and the nucleic acid molecule. The RBM22 can prevent and inhibit virus infection and relieve inflammation and damage of tissues, provides a new target spot for treatment of virus infection, and has a wide application prospect.

The present invention relates to a lymphocyte comprising a recombinant nucleic acid encoding a fusion protein comprising interleukin-15 (IL-15) fused to interleukin-21 (IL-21), and optionally further comprising a recombinant antigen receptor and further optionally rendered independent of CD28 co-stimulation and resistant to exhaustion as caused by checkpoint protein expression and activation. The invention further encompasses the use of such lymphocytes, particularly in therapeutic applications such as adoptive cell therapy for cancer, autoimmune diseases, or infectious diseases. Also included within the scope of the invention are fusion proteins comprising IL-15 and IL-21 domains, nucleic acids encoding such fusion proteins, and cells—such as lymphocytes or other suitable host cells—comprising these nucleic acids.

The present invention relates to a method for isolating and enriching pathogenic nucleic acids from a biological sample thereby reducing host nucleic acid contamination and enrich relative pathogenic DNA in the infectious disease sample and a device thereof. The method involves mixing pathogenic nucleic acid containing biological sample with a lysis buffer at a temperature between 25-35°C for partial or incomplete lysis of the sample; passing the lysed sample through a depth filter wherein the filter paper size ranges from 0.22 microns to 20 microns; passing an elution buffer by reverse plunging action and generating a vibration of 200 to 350 Hz with discontinuous pulse of 20-30 seconds for 2-5 minutes for eluting pathogenic nucleic acids into the elution buffer. The invention further provides a device for isolating and enriching pathogenic nucleic acids from a nucleic acid containing biological sample thereby reducing host nucleic acid contamination using said method.

The invention belongs to the technical field of medicines, and relates to application of an indole-3-aryl ketone derivative to preparation of a medicine for treating or preventing infectious diseases caused by staphylococcus aureus, in particular to application of the indole-3-aryl ketone derivative to preparation of a medicine for treating or preventing infectious diseases caused by drug-resistant staphylococcus aureus. The chemical structural formula of the indole-3-aryl ketone derivative disclosed by the invention is as shown in a formula I shown in the specification. Results of the invention show that the compound I (namely the indole-3-aryl ketone derivative as shown in the formula I) has strong inhibitory activity on methicillin-resistant staphylococcus aureus ATCC43300, the inhibitory effect is dependent on concentration gradient, the MIC50 value is 27.45 mu g / mL, and the MIC50 value of a positive drug streptomycin sulfate is greater than 200 mu g / mL. Therefore, the indole-3-aryl ketone derivative can be used for treating or preventing infectious diseases caused by the staphylococcus aureus.

Described herein are mushroom compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect the composition comprises an aqueous or solid fraction of a mycelium, a fermented substrate thereof, or a combination thereof optionally combined with one or more buffering agents, ethanol, and water.

This invention relates to an endogenous antimicrobial peptide from bovine milk and its applications. The antimicrobial polypeptide compound VAVALARPKHPIK is derived from endogenously enzymatically hydrolyzed bovine casein, with the amino acid sequence Val-Ala-Val-Ala-Leu-Ala-Arg-Pro-Lys-His-Pro-Ile-Lys. It exhibits broad inhibitory activity against both Gram-positive and Gram-negative bacteria, including *Porphyromonas gingivalis*, *Escherichia coli*, and *Staphylococcus aureus*. This antimicrobial peptide shows promising applications as a health supplement and / or medical device or pharmaceutical for the prevention and / or reduction of infectious diseases, as a food antimicrobial agent, in novel functional foods, pet food and animal feed additives, and in daily chemical products.

The invention provides a method for sample pooling prior to diagnostic screening for non-infectious diseases. The method comprises pooling only a portion of the obtained sample and storing another portion for later use. Sample pooling represents a more time and cost efficient way of performing diagnostic screening.

The present application relates to a kind of recombinant vaccinia virus and its use, which is deleted at least one of TK gene, F4L gene and B2R gene relative to vaccinia virus Tianlu strain.The recombinant vaccinia virus of the present application has the characteristics of low toxicity, can be completely replicated and has higher immunogenicity.Therefore, the recombinant vaccinia virus provided by the present application has higher safety and enhanced immunogenicity.The recombinant vaccinia virus provided by the present application has higher application value as vaccine, can be used for preventing the infection of poxviridae virus, and as virus vector for constructing other infectious disease vaccine and tumor vaccine etc..

The present invention relates to a method for obtaining a specific protein hydrolysate from Moringa oleifera seed cake. The present invention also relates to a protein hydrolysate from Moringa oleifera seed cake and its use as a medicament. Finally, the present invention relates to a pharmaceutical or dermatological composition comprising an effective amount of a protein hydrolysate from Moringa oleifera seed cake as an active agent, for its use as a medicament for treating fibrotic diseases and inflammatory conditions, treating cancer, treating bacterial or viral infectious diseases, and treating genetic drift and pathologies associated with skin pigmentation.

The present application describes small molecule OGG1 modulators, processes for the preparation of these compounds, and the effects of these compounds on the enzymatic and functional activity of OGG1. The method further comprises treating a variety of diseases, including cancer, cardiovascular disease, nervous system disease, inflammatory disease, autoimmune disease, and infectious disease.

A yeast strain of Saccharomyces cerevisiae var. Boulardii for the treatment and / or the prevention of infectious diseases of the oral cavity, such as dental caries and periodontal diseases. This strain can be used either alone or in combination with the inactive dry form of a yeast strain of Saccharomyces cerevisiae.